Esta referencia está disponible actualmente en inglés. La versión en español está en preparación.

Extracellular Vesicles and Dermal Papilla Signaling

Por Benn Bluestein-Veyra, M.Sc. en Química Orgánica · Actualizado el 15 de septiembre de 2026

Extracellular vesicles, usually called exosomes in the aesthetic market, are membrane-bound particles of roughly 30 to 150 nanometers that carry proteins, lipids and RNA from the cell that released them (Fig. 1).^[1] There are no FDA-approved exosome products, the FDA’s December 2019 public safety notification states so and describes exosomes used to treat diseases and conditions in humans as drugs and biological products subject to premarket review,^[2] and the human literature on vesicles and the hair follicle consists of two 2025 systematic reviews,^[3][4] a small number of pilot and open-label studies,^[5][6][7] and registered trials that are still recruiting.^[8] This page reports that literature at the level the studies support, describes the registered trials, and states the regulatory position. ExaVeyra supplies exosome material for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, described by its available formats.

It is an evidence reference. The exosome product pages on this site list the available formats and the certificate of analysis available on request for each lot; the state guides describe what a licensed practice in each state may source. Neither says what the material does, and neither does this page.

Why the dermal papilla is where the research looks

The dermal papilla is the cluster of mesenchymal cells at the base of each follicle that regulates the growth cycle through paracrine signals to the surrounding epithelium.^[9] The Wnt and beta-catenin pathway is the most studied of those signals, as the Cold Spring Harbor review by Lim and Nusse describes, and its activity is associated with entry into the growth phase (Fig. 2).^[9] Vesicles are studied in this context because they are a paracrine signaling vehicle: they carry cargo from one cell to another, and the research question is whether cargo from a given cell source changes what dermal papilla cells do.^[1]

The preclinical literature is where that question has mostly been asked.^[10] Oh and colleagues reported in Stem Cell Research and Therapy in 2024 on vesicles secreted from hyaluronic-acid-stimulated induced mesenchymal stem cells in a mouse model of androgenic alopecia,^[11] and the 2025 review by Wu and colleagues in Annals of Medicine surveys the wider animal and in vitro work.^[12] Cargo composition varies with cell source, culture conditions and isolation method, which is the reason the reviews below are careful about comparing studies that used different material.^[1][12]

What the two 2025 systematic reviews found

Al Ameer and colleagues, in Clinical, Cosmetic and Investigational Dermatology, systematically reviewed the clinical evidence across alopecia types and vesicle sources and characterized it as early, heterogeneous in source and preparation, and short on randomized controlled trials.^[3] Darwish and colleagues, in Cureus, systematically compared the vesicle literature with platelet-rich plasma and minoxidil in androgenetic alopecia and reached a more favorable conclusion: the authors ranked exosome-based approaches first for hair regrowth and safety, PRP second and minoxidil as the most accessible but more limited option, and called for further research to guide clinical decisions.^[4] A 2025 scoping review by Gupta and colleagues for an ISHRS committee described PRP as the most studied modality and stem cell and exosome evidence as promising but still limited.^[13]

Both reviews are cited here for their characterization of the field, because neither could pool across the heterogeneous preparations it found.^[3][4] That distinction, between a review that describes a literature and one that quantifies it, is the one a reader most needs when a supplier hands over a citation list, and the clinic-launch guide on reading the evidence walks through it.

The human studies, by design

The table describes designs and materials, and the difference between rows is the point. A plant-derived formulation, an exosome complex applied with microneedling, and umbilical cord vesicles in a registered trial are three different materials, and each needs its own evidence.^[5][6][14] The study design badges beside the literature citations below carry the same information in a form a reader can scan.

The registered trials

ClinicalTrials.gov lists interventional trials of mesenchymal stem cell-derived exosomes in androgenetic alopecia that are recruiting as of this review, including a study of umbilical cord mesenchymal stem cell-derived exosomes at a Chinese university hospital with an estimated primary completion date in 2026.^[8] The Shenzhen protocol published in the FASEB Journal in 2026 describes a randomized controlled trial in 59 men aged 18 to 35 with a dose-escalation phase.^[14] Registration establishes that a trial was planned and registered, and the result is established when it is reported; the regulatory reference on this site on exosome clinical trials sets out that distinction across the whole registry.

The regulatory position

The FDA’s consumer information on regenerative medicine products sets out the same position for stem cell and exosome products together.^[15] For researchers who want to study vesicles clinically, the regulatory references on this site describe the investigational biologic pathway and the manufacturing expectations that apply to it.

ExaVeyra supplies exosome material for topical aesthetic use by licensed practitioners and for laboratory and IND-authorized clinical research, with a lot-specific certificate of analysis, and describes it on this site by its available formats. Whether a given practice may use the material, and for what, is governed by federal law and by the practitioner’s own license, which is what the state guides on this site are for.